Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To explore the survival benefit of the gefitinib combined with radiotherapy as adjuvant
therapy for completely resected patients with Pathological stage IIIA-N2 NSCLC harbouring
sensitive mutations of EGFR.
Phase:
N/A
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Collaborators:
Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences China-Japan Friendship Hospital Chinese PLA General Hospital